Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 6/20 | 0.43 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | ECE1 | P42892 | 2/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.37 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30830405 | 1.00 | NOD1 (0.48) | NOD1ACEITGB1ITGA4DPP4 | |
| SCHEMBL2545708 | 1.00 | NOD1 (0.48) | NOD1ACEITGB1ITGA4DPP4 | |
| SCHEMBL10704006 | 0.93 | NOD1 (0.44) | NOD1ACEITGB1ITGA4DPP4 | |
| SCHEMBL9326107 | 0.93 | NOD1 (0.50) | NOD1ACEITGB1ITGA4DPP4 | |
| SCHEMBL445484 | 0.87 | NOD1 (0.46) | NOD1ACEITGB1ITGA4DPP4 | |
| SCHEMBL23154560 | 0.85 | NOD1 (0.46) | NOD1ACEDPP4ECE1DPP8 | |
| SCHEMBL8419719 | 0.84 | ACE (0.46) | ACEITGB1ITGA4FOLH1NAALAD2 | |
| SCHEMBL8416407 | 0.84 | ACE (0.46) | ACEITGB1ITGA4FOLH1NAALAD2 | |
| SCHEMBL8416400 | 0.84 | ACE (0.46) | ACEITGB1ITGA4FOLH1NAALAD2 | |
| SCHEMBL9810324 | 0.82 | SLC7A5 (0.50) | ACEITGB1ITGA4FOLH1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110205282-B | Cell culture medium comprising small peptides | 生命技术公司 | 2024-07-05 | — | — | CN | claimed |
| EP-0264953-B1 | USE OF N,N'-BIS-L-AMINO ACID-L-CYSTIN PEPTIDES IN AMINO ACID PREPARATIONS FOR ORAL AND PARENTERAL ADMINISTRATION | PFRIMMER KABI GMBH & CO. KG (DE) | 1991-05-08 | — | — | EP | claimed |
| US-12529029-B2 | Cell culture medium comprising small peptides | Life Technologies Corporation (US) | 2026-01-20 | — | — | US | disclosed |
| CN-106520658-B | Cell culture medium comprising small peptides | 生命技术公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-110205282-B | Cell culture medium comprising small peptides | 生命技术公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-117940556-A | Composition comprising dipeptide and trace element | 赢创运营有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20230365919-A1 | CELL CULTURE MEDIUM COMPRISING SMALL PEPTIDES | Life Technologies Corporation | 2023-11-16 | — | — | US | disclosed |
| EP-4170016-A1 | CELL CULTURE MEDIUM COMPRISING SMALL PEPTIDES | Life Technologies Corporation (US) | 2023-04-26 | — | — | EP | disclosed |
| EP-3165600-B1 | CELL CULTURE MEDIUM COMPRISING SMALL PEPTIDES | LIFE TECHNOLOGIES CORP (US) | 2022-11-02 | — | — | EP | disclosed |
| EP-3168295-B1 | CELL CULTURE MEDIUM COMPRISING SMALL PEPTIDES | LIFE TECHNOLOGIES CORP (US) | 2022-11-02 | — | — | EP | disclosed |
| US-20220275325-A1 | CELL CULTURE MEDIUM COMPRISING SMALL PEPTIDES | LIFE TECHNOLOGIES CORP (US) | 2022-09-01 | — | — | US | disclosed |
| EP-2561065-B1 | CELL CULTURE MEDIUM COMPRISING SMALL PEPTIDES | LIFE TECHNOLOGIES CORP (US) | 2016-11-09 | — | — | EP | disclosed |
| EP-2610338-A1 | METHOD FOR PRODUCING SUBSTANCE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2013-07-03 | — | — | EP | disclosed |
| US-20130130317-A1 | METHOD FOR PRODUCING SUBSTANCE | KYOWA HAKKO KIRIN CO., LTD (JP) | 2013-05-23 | — | — | US | disclosed |
| EP-2561065-A2 | CELL CULTURE MEDIUM COMPRISING SMALL PEPTIDES | Life Technologies Corporation (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20110262965-A1 | CELL CULTURE MEDIUM COMPRISING SMALL PEPTIDES | Life Technologies Corporation (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2011133902-A2 | CELL CULTURE MEDIUM COMPRISING SMALL PEPTIDES | Life Technologies Corporation (US) | 2011-10-27 | — | — | WO | disclosed |
| EP-0264953-B1 | USE OF N,N'-BIS-L-AMINO ACID-L-CYSTIN PEPTIDES IN AMINO ACID PREPARATIONS FOR ORAL AND PARENTERAL ADMINISTRATION | PFRIMMER KABI GMBH & CO. KG (DE) | 1991-05-08 | — | — | EP | disclosed |
| US-4968696-A | CHRONIC UREMIA OR HEPATIC CIRRHOSIS | PFRIMMER + CO. PHARMAZEUTISCHE WERKE ERLANGEN GMBH + CO. KG (DE) | 1990-11-06 | — | — | US | disclosed |
| WO-1988003150-A2 | N,N'-BIS-AMINO ACID-L-CYSTINE-PEPTIDE-CONTAINING AMINO ACID PREPARATIONS FOR ORAL AND PARENTERAL ADMINISTRATION | PFRIMMER + CO. PHARMAZEUTISCHE WERKE ERLANGEN GMBH (DE) | 1988-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12529029-B2 | Cell culture medium comprising small peptides | SLC7A11, SLC7A5, SLC6A15 | NOD1 2186/4885ACE 2179/4885ITGB1 2805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.